| Company | Location | Date | Amt. (M) | Details |
| Adnavance Technologies Inc. | Vancouver, British Columbia | 2/26 | C$3.7 ($3.77) | Completed a Series B financing of $3.77M led by Working Opportunity Fund, managed by GrowthWorks Capital Ltd., JovInvestment Management and Business Development Bank of Canada |
| Affimed Therapeutics AG | Heidelberg, Germany | 2/20 | €5 ($7.3) | Affimed closed a $7.3M second tranche of its Series B financing provided by Novo NordiskBiotech Fund |
| Affomix Corp. | New Haven, Conn. | 2/21 | $7 | Affomix completed a $7M Series A venture round; investors were Four Seasons Ventures, Connecticut Innovations and Elm Street Ventures |
| Albireo AB | Gothenburg, Sweden | 2/20 | $40 | Albireo is raising $40M in a Series A round, bringing in $27M in the first closing and the rest within the next few weeks; it was led by Nomura Phase4 Ventures, which was joined by TVM Capital and Scottish Widows Investment |
| Arriva Pharmaceuticals | Amsterdam, the Netherlands | 2/28 | $6 | Arriva completed a financing of $6M led by Nordic Biotech II K/S and with participation from MPM BioVentures |
| BioVascular Inc. | San Diego | 2/7 | $10.87 | BioVascular raised $10.87M in a Series C round led by BB Biotech Ventures and joined by Merck KGaA and Domain Associates LLC |
| Cellectricon AB | Gothenburg, Sweden | 2/21 | SEK89($14.1) | Cellectricon's share issue provide the company with $14.1M |
| Gastrotech Pharma A/S | Copenhagen, Denmark | 2/11 | $6 | Gastrotech completed a $6M Series D round led by CAT Invest I A/S, with participation from Nordic Biotech, BML Healthcare I LP and 123-MultiNova Europe |
| Heptares Therapeutics Ltd. | London | 2/19 | ND | Heptares' seed investor MVM Life Sciences Partners contributed an undisclosed amount of additional seed funding |
| Ocera Therapeutics Inc. | San Diego | 2/19 | $35.5 | Ocera raised $35.5M in a Series C financing led by Montagu Newhall Associates, which was joined by InterWest Partners LLC, AgeChem Venture Fund LP, Wasatch Advisors Inc. affiliate Cross Creek Capital, FinTech GIMB Fund LP and CDIB BioScience Venture Management, as well as Domain Associates LLC, Sofinnova Ventures and Thomas, McNerney & Partners LLC |
| Optimata Ltd. | Ramat Gan, Israel | 2/13 | $1.5 | Optimata completed a private placement of $1.5M from a new group of private European investors |
| Population Genetics Technologies Ltd. | Cambridge, UK | 2/20 | £3.8 ($7.4) | Population Genetics raised $7.4M in a Series A financing; investors were Auriga Partners, Noble Fund Managers and Compass Genetics Investors LLC |
| Q Therapeutics Inc. | Salt Lake City | 2/18 | $15 | Q Therapeutics closed on a first tranche of its $15M Series B financing, in which Invitrogen Corp. was one of the investors |
| Taligen TherapeuticsInc. | Aurora, Colo. | 2/1 | $65 | Taligen closed a tranched Series B financing round, raising $65M; Alta Partners and Clarus Ventures led the round; Sanderling Ventures and Tango/High Country Venture LLC participated |
| TyRx Pharma Inc. | Monmouth Junction, N.J. | 2/28 | $25 | TyRx raised $25M in a venture capital round led by Clarus Ventures and co-led by Pappas Ventures |
| Vitro Biopharma Inc. | Aurora, Colo. | 2/5 | $0.5 | Vitro Biopharma completed a $500,000 financing that included the sale of 1.25M shares of common stock for $125,000, along with warrants to purchase up to an additional 2M shares of common stock exercisable in tranches |
|
Notes: Currency conversions are based on exchange rates at the time of the deal. ** Denotes the date the item ran in BioWorld International.ND = Not disclosed. | ||||
